1 January 2011PatentsTania Obranovich

Banning the patenting of biological materials in Australia: fact v fiction

An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

Why US patent reform is ‘essential’ for US economic prosperity and security

G1/23 ruling: Why a pending EPO decision threatens decade-old products

Lululemon counsel on why Nike's 'Flyknit' claim construction faltered

Lenovo’s legal leader: We should be ‘enablers, not blockers’

Sterlington expands patent litigation team with new hire

‘Now is the time to scale rapidly’: Microsoft supports AI patent tool

WATCH: Engaging inventors to ensure you obtain the best IP

USPTO speeds up patent issuance amid widespread agency changes

Banning the patenting of biological materials in Australia: fact v fiction

Editor's picks

Editor's picks

More articles